CO167 The Incremental Benefit Provided by Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Multiple Myeloma (MM) and Diffuse Large B-Cell Lymphoma (DLBCL) When Compared to Real-World Clinical Practice (RWCP)
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.243
https://www.valueinhealthjournal.com/article/S1098-3015(22)02447-0/fulltext
Title :
CO167 The Incremental Benefit Provided by Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Multiple Myeloma (MM) and Diffuse Large B-Cell Lymphoma (DLBCL) When Compared to Real-World Clinical Practice (RWCP)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02447-0&doi=10.1016/j.jval.2022.09.243
First page :
Section Title :
Open access? :
No
Section Order :
12048